Modelling Ageing Blood Disorders Using Induced Pluripotent Stem Cells (iPSCs)

Myelodysplastic syndromes (MDS) are a type of blood cancer that predominantly affect older adults, with a median age at diagnosis of 68 to 75 years. MDS originates at the level of haematopoietic stem/progenitor cells (HSPCs) and often progress to acute myeloid leukaemia (AML). There is no cure for MDS. Current therapies fail in 50-60% of patients, but how patients might be stratified to identify those likely to respond from those who fail therapy is not clear.

Our group is interested on understanding the molecular mechanisms of disease progression and therapy resistance. Our work and the unique critical tools we have developed, including induced pluripotent stem cells (iPSCs) from patients with MDS, provide the opportunity to address these questions in the stem and progenitor compartment.

This project will further investigate the contribution of specific mutations to the disease phenotype how these mutations influence genome instability in HSPCs and define the vulnerabilities this influence brings.

Person Specification

Applicants should have a strong background in stem cell/molecular biology. They should have a commitment to research in blood disorders and hold or realistically expect to obtain at least an Upper Second Class Honours Degree in a relevant subject.

How to apply

Applications should be directed to p.garcia@bham.ac.uk. To apply, please send:

·        A Detailed CV, including your nationality and country of birth;

·        Names and addresses of two referees;

·        A covering letter highlighting your research experience/capabilities;

·        Copies of your degree transcripts;

·        Evidence of your proficiency in the English language, if applicable.

Applicants will be required to attend an interview. This can be conducted face –to –face, by telephone or skype